Bayer HealthCare has announced its support for World Health Organization (WHO) efforts to combat tuberculosis (TB) by making a new delivery of drugs available for use in China.
The company will work with the Stop TB Partnership to provide 620,000 tablets of the antibiotic moxifloxacin to the WHO, which will then allocate the treatments for use by China's national TB programme.
A broad-spectrum antibiotic indicated for treatment of several acute bacterial infections, moxifloxacin is not currently approved as a TB therapy but can have uses as part of a second-line regimen.
Currently, Bayer is working alongside the Global Alliance for TB Drug Development to conduct research into the antibiotic as a potential treatment for drug-susceptible pulmonary TB.
Dr Jorg Reinhardt, chairman of the board of management of Bayer HealthCare, said: "We have decided to make moxifloxacin available to provide quick support to those patients in need."
Earlier this month, the company published positive new clinical trial data to support the efficacy of Xarelto, its therapy for stroke prevention among atrial fibrillation patients.See all the latest jobs in Pharmaceutical